Boswellia (AKBA) vs Diclofenac Topical
A side-by-side research comparison of Boswellia (AKBA) and Diclofenac Topical across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Boswellia (AKBA) | Diclofenac Topical |
|---|---|---|
| Full name | Boswellia Serrata Extract (AKBA) | Diclofenac Sodium Topical Gel (Voltaren) |
| Category | Pain & Inflammation | Pain & Inflammation |
| Status | OTC supplement | FDA Approved (OTC) |
| Mechanism | AKBA (acetyl-11-keto-beta-boswellic acid) selectively inhibits 5-lipoxygenase (5-LOX), reducing pro-inflammatory leukotrienes. This targets a different inflammatory pathway than NSAIDs (which act on COX), sparing the stomach lining. | Inhibits cyclooxygenase-1 and -2 (COX-1/2) locally in tissue, reducing prostaglandin E2 synthesis at the inflammation site. Topical delivery achieves therapeutic tissue concentrations with plasma levels <5% of oral dosing. |
| Molecular weight | 512.7 Da (AKBA) | 318.13 Da (sodium salt) |
| Half-life | ~6 hours (AKBA) | ~1-2 hours (plasma); tissue penetration lasts 12+ hours |
| Bioavailability | Low; improved by AKBA-standardized and phytosome forms | ~6% systemic (topical); local tissue levels therapeutic |
| Typical dose | 100-250 mg AKBA-standardized, 1-2x daily | 4g gel (1% or 2%) per joint |
| Frequency | 1-2x daily | 3-4x daily |
| Route | Oral capsule | Topical gel |
Boswellia (AKBA) reported benefits
- Reduces joint pain and stiffness
- Non-NSAID (stomach-sparing) anti-inflammatory
- Supports gut inflammation (IBD research)
- Cartilage protection
- Anti-inflammatory via 5-LOX inhibition
Diclofenac Topical reported benefits
- Localized pain relief
- Minimal systemic side effects
- Joint and tendon inflammation
- Post-workout recovery
- No GI ulcer risk
- OTC availability
Related comparisons
Research and educational reference only. Not medical advice.